Breaking News Instant updates and real-time market news.

NERV

Minerva

$6.80

-0.1 (-1.45%)

08:34
04/09/18
04/09
08:34
04/09/18
08:34

Minerva screens first patient in Phase 2b trial of MIN-117 to treat MDD

Minerva Neurosciences announced the screening of the first patient in a Phase 2b trial of MIN-117 to reduce the symptoms of patients diagnosed with major depressive disorder. The primary objective of the trial is to evaluate the efficacy of two fixed doses of MIN-117, 5.0 milligrams and 2.5 mg, compared with placebo in reducing the symptoms of major depression as measured by the change in the Montgomery-Asberg Depression Rating Scale total score over six weeks of treatment. Secondary objectives include: assessment of the change from baseline in symptoms of anxiety using the Hamilton Anxiety Scale; the change in severity of illness using the Clinical Global Impression of Severity Scale and Clinical Global Impression of Improvement Scale; and safety over six weeks of treatment. The study population will consist of adults with a diagnosis of moderate or severe MDD with anxious distress and without psychotic features. Based upon previous clinical observations, the company believes that patients with MDD who also have symptoms of anxiety may benefit from treatment with MIN-117. Approximately 324 patients are expected to be enrolled at approximately 40 sites in the U.S. and Europe. Patients will be randomized to one of three arms, including placebo and the two dosage arms, in a 2:1:1 ratio, resulting in approximately 162 patients in the placebo group and 81 patients in each of the two MIN-117 treatment groups. The study design includes a screening phase of up to three weeks, a six-week double-blind treatment phase and a two-week post- study follow-up period. Top line results of the trial are expected in 1H19.

NERV Minerva
$6.80

-0.1 (-1.45%)

09/01/17
SBSH
09/01/17
INITIATION
Target $11
SBSH
Buy
Minerva Neurosciences initiated with a Buy at Citi
Citi analyst Joel Beatty started Minerva Neurosciences with a Buy rating and $11 price target. The Phase 3 trial for lead agent MIN-101 in negative symptoms of schizophrenia is well positioned for success, Beatty tells investors in a research note. He sees negative symptoms of schizophrenia as an attractive market opportunity because there are no approved drugs for the indication.
09/01/17
09/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Bernstein. 2. Minerva (NERV) Neurosciences initiated with a Buy at Citi. 3. VMware (VMW) resumed with a Sector Weight at KeyBanc. 4. Provident Financial (PFS) initiated with a Neutral at DA Davidson. 5. Maximus (MMS) initiated with a Neutral at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MDT

Medtronic

$90.40

-3.28 (-3.50%)

06:48
11/20/18
11/20
06:48
11/20/18
06:48
Hot Stocks
Medtronic CEO says 'we are executing on multiple fronts' »

"This was an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

JDWPY

JD Wetherspoon

$0.00

(0.00%)

06:47
11/20/18
11/20
06:47
11/20/18
06:47
Initiation
JD Wetherspoon initiated  »

JD Wetherspoon initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MATX

Matson

$40.86

-0.32 (-0.78%)

06:47
11/20/18
11/20
06:47
11/20/18
06:47
Downgrade
Matson rating change  »

Matson downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

JEC

Jacobs Engineering

$72.96

-1.2 (-1.62%)

06:47
11/20/18
11/20
06:47
11/20/18
06:47
Earnings
Jacobs Engineering reports Q4 adj. EPS $1.31, consensus $1.24 »

Reports Q4 revenue $4.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

  • 19

    Feb

MDT

Medtronic

$90.40

-3.28 (-3.50%)

06:47
11/20/18
11/20
06:47
11/20/18
06:47
Earnings
Medtronic backs FY19 adjusted EPS view $5.10-$5.15, consensus $5.12 »

For fiscal year 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

MDT

Medtronic

$90.40

-3.28 (-3.50%)

06:45
11/20/18
11/20
06:45
11/20/18
06:45
Earnings
Medtronic reports Q2 adjusted EPS $1.22, consensus $1.15 »

Reports Q2 revenue $7.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

TESS

Tessco

$11.11

-0.12 (-1.07%)

06:45
11/20/18
11/20
06:45
11/20/18
06:45
Upgrade
Tessco rating change  »

Tessco assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

FB

Facebook

$131.62

-7.93 (-5.68%)

06:45
11/20/18
11/20
06:45
11/20/18
06:45
Periodicals
Singapore lawmaker blasts Facebook over refusal to take down post, Reuters says »

Singapore senior minister…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ATV

Acorn International

$21.44

0.25 (1.18%)

06:44
11/20/18
11/20
06:44
11/20/18
06:44
Hot Stocks
Acorn International announces partnership with Shanghai Media Group »

Acorn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$63.00

-7.545 (-10.70%)

06:43
11/20/18
11/20
06:43
11/20/18
06:43
Recommendations
Square analyst commentary  »

Square price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 12

    Dec

  • 18

    Dec

CBM

Cambrex

$47.67

0.41 (0.87%)

06:42
11/20/18
11/20
06:42
11/20/18
06:42
Hot Stocks
Cambrex to acquire Avista Pharma Solutions for approximately $252M »

Cambrex announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QLYS

Qualys

$69.24

-5.355 (-7.18%)

06:41
11/20/18
11/20
06:41
11/20/18
06:41
Upgrade
Qualys rating change  »

Qualys upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 04

    Dec

  • 09

    Jan

JD

JD.com

$21.09

-1.95 (-8.46%)

06:38
11/20/18
11/20
06:38
11/20/18
06:38
Downgrade
JD.com rating change  »

JD.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$21.09

-1.95 (-8.46%)

06:35
11/20/18
11/20
06:35
11/20/18
06:35
Periodicals
JD.com CEO says focus will be on strategy, new businesses, Yicai reports »

JD.com founder and CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRL

Hormel Foods

$45.36

-0.535 (-1.17%)

06:35
11/20/18
11/20
06:35
11/20/18
06:35
Earnings
Breaking Earnings news story on Hormel Foods »

Hormel Foods sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TGT

Target

$77.13

-1.9 (-2.40%)

06:34
11/20/18
11/20
06:34
11/20/18
06:34
Earnings
Breaking Earnings news story on Target »

Target sees FY18 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

TGT

Target

$77.13

-1.9 (-2.40%)

06:34
11/20/18
11/20
06:34
11/20/18
06:34
Hot Stocks
Breaking Hot Stocks news story on Target »

Target sees Q4 SSS up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

MMS

Maximus

$63.91

-2.05 (-3.11%)

06:33
11/20/18
11/20
06:33
11/20/18
06:33
Earnings
Maximus sees FY19 revenue $2.95B-$3.0B, consensus $2.53B »

Sees FY19 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TGT

Target

$77.13

-1.9 (-2.40%)

06:33
11/20/18
11/20
06:33
11/20/18
06:33
Earnings
Target reports Q3 adj. EPS $1.09, consensus $1.12 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

HRL

Hormel Foods

$45.36

-0.535 (-1.17%)

06:32
11/20/18
11/20
06:32
11/20/18
06:32
Earnings
Hormel Foods reports Q4 adj. EPS 51c, consensus 49c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MMS

Maximus

$63.91

-2.05 (-3.11%)

06:31
11/20/18
11/20
06:31
11/20/18
06:31
Earnings
Maximus reports Q4 revenue $558.4M, consensus $587.58M »

Reports Q4 EPS 71c vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HSDT

Helius Medical

$8.02

-0.08 (-0.99%)

06:31
11/20/18
11/20
06:31
11/20/18
06:31
Upgrade
Helius Medical rating change  »

Helius Medical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WWD

Woodward

$79.45

-2.46 (-3.00%)

06:30
11/20/18
11/20
06:30
11/20/18
06:30
Upgrade
Woodward rating change  »

Woodward upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QEP

QEP Resources

06:27
11/20/18
11/20
06:27
11/20/18
06:27
Upgrade
QEP Resources rating change  »

QEP Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$45.12

-1.48 (-3.18%)

06:27
11/20/18
11/20
06:27
11/20/18
06:27
Downgrade
Western Digital rating change  »

Western Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.